VITRO AND IN VIVO CHARACTERIZATION OF EYP001 A NOVEL, POTENT AND SELECTIVE FXR AGONIST NOW IN A PHASE 2 CLINICAL TRIAL IN NASH

被引：0

作者：

Radreau, Pauline ^{[1
]}

Joly, Stephane ^{[1
]}

Dubos, Claire ^{[1
]}

Vonderscher, Jacky ^{[1
]}

Scalfaro, Pietro ^{[1
]}

Meldrum, Eric ^{[1
]}

Darteil, Raphael ^{[1
]}

机构：

[1] Enyo Pharma SA, Lyon, France

来源：

HEPATOLOGY | 2019年 / 70卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

2140

引用

页码：1267A / 1267A

页数：1

共 50 条

[1] IN VITRO CHARACTERIZATION OF EYP001 A NOVEL, POTENT AND SELECTIVE FXR AGONIST ENTERING PHASE 2 CLINICAL TRIALS IN CHRONIC HEPATITIS B
Darteil, Raphael
Joly, Stephane
Radreau, Pauline
Porcherot, Marine
Vonderscher, Jacky
Scalfaro, Pietro
Meldrum, Eric
Andre, Patrice
HEPATOLOGY, 2019, 70 : 60A - 60A
[2] Characterization of EYP001 a novel, potent and selective FXR agonist in in vitro 3D human liver models of NASH
Radreau-Pierini, Pauline
Joly, Stephane
Vonderscher, Jacky
Scalfaro, Pietro
Eric, Meldrum
Darteil, Raphael
JOURNAL OF HEPATOLOGY, 2020, 73 : S453 - S453
[3] Effect of a novel synthetic FXR agonist EYP001 on hepatitis B virus replication in HepaRG cell line and primary human hepatocytes
Radreau, Pauline
Porcherot, Marine
Vonderscher, Jacky
Lotteau, Vincent
Andre, Patrice
HEPATOLOGY, 2015, 62 : 1014A - 1014A
[4] The selective FXR agonist EYP001 is well tolerated in healthy subjects and has additive anti-HBV effect with nucleoside analogues in HepaRG cells
Joly, S.
Porcherot, M.
Radreau, P.
Vonderscher, J.
Andre, P.
Meldrum, E.
Arold, G.
de Rooij, J. Van de Wetering
Staner, C.
Laveille, C.
Scalfaro, P.
JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S690 - S690
[5] In vitro and in vivo characterization of the potent and selective JAK2 inhibitor
Markovtsov, Vadim
Tonkin, Elizabeth
Fang, Shuling
Liu, Chian
Gelman, Marina
Lang, Wayne
McLaughlin, John
Bhamidipati, Sohasekhar
Clough, Jeffrey
Singh, Rajinder
Low, Caroline
Reitsma, Andrea
Park, Gary
Sweeney, David
Pine, Polly
Torneros, Allan
Clemens, George
Duan, Matt
Payan, Donald
Holland, Sacha
Hitoshi, Yasumichi
CANCER RESEARCH, 2009, 69
[6] Lorcaserin, a novel selective human 5-Hydroxytryptamine2C agonist:: In vitro and in vivo pharmacological characterization
Thomsen, William J.
Grottick, Andrew J.
Menzaghi, Frederique
Reyes-Saldana, Hazel
Espitia, Stephen
Yuskin, Diane
Whelan, Kevin
Martin, Michael
Morgan, Michael
Chen, Weichao
Al-Shamma, Hussien
Smith, Brian
Chalmers, Derek
Behan, Dominic
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 325 (02): : 577 - 587
[7] Cardiovascular effects of a novel, potent and selective phosphodiesterase 5 inhibitor, DMPPO: In vitro and in vivo characterization
Delpy, E
deGouville, ACL
BRITISH JOURNAL OF PHARMACOLOGY, 1996, 118 (06) : 1377 - 1384
[8] In vitro and in vivo characterization of PF-044189948, a novel, potent and selective prostaglandin EP2 receptor antagonist
af Forselles, K. J.
Root, J.
Clarke, T.
Davey, D.
Aughton, K.
Dack, K.
Pullen, N.
BRITISH JOURNAL OF PHARMACOLOGY, 2011, 164 (07) : 1847 - 1856
[9] In vitro and in vivo pharmacology of SAR125844, a potent and selective intravenous MET kinase inhibitor undergoing Phase I clinical trial
Goulaouic, Helene
Kenigsberg, Mireille
Delaisi, Christine
Begassat, Frangoise
Do-Vale, Veronigue
Mestadier, Jessica
Bonche, Fabrice
Benard, Tsiala
Nicolas, Jean-Paul
Calvet, Loreley
Egile, Coumaran
Nemecek, Conception
Lengauer, Christoph
CANCER RESEARCH, 2012, 72
[10] In vitro and in vivo profiling of fadolmidine, a novel potent α2-adrenoceptor agonist with local mode of action
Lehtimaki, Jyrki
Leino, Tiina
Koivisto, Ari
Viitamaa, Timo
Lehtimaki, Tarja
Haapalinna, Antti
Kuokkanen, Katja
Virtanen, Raimo
EUROPEAN JOURNAL OF PHARMACOLOGY, 2008, 599 (1-3) : 65 - 71

← 1 2 3 4 5 →